Sign up
Pharma Capital
EPIC: AQS
Market: TSX-V:AQS
OTCMKTS:AQSZF
52-week High/Low: C$0.41 / C$0.13
Sector: Pharma & Biotech
Market Cap: C$12.87M

We are a rapidly growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus’ sales and marketing efforts are based in Canada, targeting highly specialized therapeutic areas including neurology, ophthalmology and transplant.

Aequus is developing a pipeline of products in neurology and psychiatry with a goal of...

Aequus Pharmaceuticals Inc

www.aequuspharma.ca

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Aequus Pharmaceuticals Inc

Aequus Pharmaceuticals Inc Snapshot

Doug Janzen
CHAIRMAN & CHIEF EXECUTIVE OFFICER
Doug Janzen has been involved in the Life Sciences industry for the past 19 years. He is currently the Founder and President of Northview Ventures, an organization which invests in and provides strategic advisory services to a number of technology companies. Mr Janzen was part of the founding group of Aequus Pharmaceuticals. Previously, Mr Janzen was President and CEO of Cardiome Pharma, a NASDAQ listed drug development company that raised over $300 million from investors, and completed over $1 billion in licensing deals during his tenure. In 2010, Cardiome’s lead product, Brinavess, was approved and launched in Europe by Merck. Prior to that, he was an investment banker with Cormark Securities, acting as Managing Director of Life Sciences. Mr Janzen is Past Chair of LifeSciences BC, has served as a Director with Biotech Canada and currently sits as a Director on a number of public and private boards. He is a past winner of Business in Vancouver’s Top 40 Under 40 Award.

Anne Stevens MHA
CHIEF OPERATING OFFICER & DIRECTOR
Ms Stevens has over ten years of progressive experience in the Pharmaceutical, Biotech, and Medical Device industry. Anne is the Co-Founder and Senior Partner of Northview Ventures, an entity which invests in and provides strategic advisory services to a number of life sciences companies. Ms Stevens was part of the founding group of Aequus Pharmaceuticals and previously held the title of VP of Corporate Development. Prior to her involvement with Aequus, Ms Stevens served as the Corporate and External Affairs Analyst for Cardiome Pharma, where she was responsible for strategic planning and value analysis of internal R&D. Ms Stevens’ earlier experience includes 5 years with Bayer HealthCare, where she was responsible for the commercial success and business development of a portfolio of products within several key therapeutic areas.

Ann Fehr CPA • CGA
CHIEF FINANCIAL OFFICER
Ms. Fehr is the Principal at Fehr & Associates, and has held a number of senior level positions including having served as CFO of Carrus Capital Corporation (formerly BioWest Therapeutic Inc.), Global Minerals Ltd., and other companies listed on the TSX. During the course of her management and consulting career, Ms. Fehr has led a number of companies through significant change and corporate milestones such as public listing applications, mergers and acquisitions, as well as strategic planning and execution. Ms. Fehr is also an active volunteer in the community. Since 2013, she has been Treasurer and a Director for the Boys and Girls Clubs of South Coast BC.

Donald McAfee PhD
CHIEF SCIENTIFIC OFFICER
Dr. McAfee has been a scientist and manager in academia and industry for more than 40 years. Most recently, he was Cardiome Pharma’s Chief Scientific Officer after serving as Vice President of New Product Development since 2004. Previously, he was Founder, Chief Executive Officer, and Chief Technical Officer of Aderis Pharmaceuticals, Inc. where he led the introduction of a number of clinical candidates including a therapeutic patch for Parkinson’s disease, now marketed.

Ian Ball
CHIEF COMMERCIAL OFFICER
Ian joined the Pharma industry in 1995 and has spent the last 20 years in various sales and marketing roles for multinational companies. His experience is unique; an experienced General Manager across multiple territories, a top rated medical representative, award winning marketer, recognized expert in commercial supply chain within Pharma and an industry leader in parallel trade management. Ian has led Board level initiatives in Novartis and consulted with other Pharma companies on portfolio management and commercial strategy.

Ian’s most recent role was as CEO of TeOra Health, a specialty pharma company with a focus on Ophthalmology and Transplant which was acquired by Aequus Pharmaceuticals Inc.

James Purdy MBA
DIRECTOR OF OPERATIONS
James has been with Aequus from the beginning, managing a wide range of key functional areas within the company that include finance, market research, deal diligence, and sales operations. In addition, James currently works as an Associate with Northview Ventures, a life science focused investment and consulting firm that works to commercialize innovative technologies. In this role, James works closely with academic researchers to help transform their research in the lab into a successful commercial entity. Prior to joining Aequus, James worked in sales as an account manager with Life Technologies (acquired by Thermo Fisher). Handling a research and diagnostics portfolio in genetic sequencing, qPCR, and Cell Analysis, James was recognized as the Top Account Executive in North America. James currently holds a BSc in Molecular Biology from McMaster University and an MBA from the Sauder School of Business at UBC.

2820 - 200 Granville St, Vancouver BC V6C 1S4 Canada
604 336 7906
[email protected]

View full AQS profile View Profile
View All

Executive video interviews

VIEW ALL VIDEOS

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.